Home > Drugs A – Z > Insulin Detemir (By injection)

Insulin Detemir (By injection)

Treats diabetes.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Insulin detemir is a long-acting type of insulin. Insulin is one of many hormones that help the body turn the food we eat into energy. This is done by using the glucose (sugar) in the blood as quick energy. Also, insulin helps us store energy that we can use later. When you have diabetes mellitus, your body cannot make enough insulin or does not use insulin properly. So, you must take additional… Read more
Brand names include
Levemir, Levemir FlexPen, Levemir FlexTouch
Drug classes About this
Antidiabetic

What works? Research summarized

Evidence reviews

Insulin detemir versus insulin glargine for type 2 diabetes mellitus

The two long‐acting insulin analogues (artificial insulins), insulin detemir or insulin glargine differ in their mechanism of attaining protracted action, leading to possible differences in glycaemic control and safety outcomes. Several studies have compared either insulin detemir or insulin glargine to NPH (Neutral Protamin Hagedorn) insulin. Research directly comparing both long‐acting insulin analogues is limited.

A meta-analysis of clinical therapeutic effect of insulin glargine and insulin detemir for patients with type 2 diabetes mellitus

BACKGROUND: Insulin have been recommended to decrease glycosylated hemoglobin (HbA1c) level in type 2 diabetes mellitus (T2DM) patients whose blood glucose control are unsatisfactory by using oral hypoglycemic drugs.

Long acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus

NPH (Neutral Protamine Hagedorn) insulin is the current standard for basal insulin in the blood glucose lowering therapy in people with type 2 diabetes mellitus. The mode of action of this insulin is highly variable, which may be the cause for the difficulties some people with diabetes have to achieve current goals for long‐term metabolic control. Therefore, new insulins which are thought to show more favourable properties of action have been developed: insulin glargine and insulin detemir. Because of their theoretical advantages, it is thought that treatment with these new insulin analogues might lead to a beneficial effect, for example less hypoglycaemia or a better metabolic control, possibly resulting in higher quality of life and treatment satisfaction less late diabetic complications such as problems with eyes, kidneys or feet and myocardial infarction, stroke or death.

See all (55)

Summaries for consumers

Insulin detemir versus insulin glargine for type 2 diabetes mellitus

The two long‐acting insulin analogues (artificial insulins), insulin detemir or insulin glargine differ in their mechanism of attaining protracted action, leading to possible differences in glycaemic control and safety outcomes. Several studies have compared either insulin detemir or insulin glargine to NPH (Neutral Protamin Hagedorn) insulin. Research directly comparing both long‐acting insulin analogues is limited.

Long acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus

NPH (Neutral Protamine Hagedorn) insulin is the current standard for basal insulin in the blood glucose lowering therapy in people with type 2 diabetes mellitus. The mode of action of this insulin is highly variable, which may be the cause for the difficulties some people with diabetes have to achieve current goals for long‐term metabolic control. Therefore, new insulins which are thought to show more favourable properties of action have been developed: insulin glargine and insulin detemir. Because of their theoretical advantages, it is thought that treatment with these new insulin analogues might lead to a beneficial effect, for example less hypoglycaemia or a better metabolic control, possibly resulting in higher quality of life and treatment satisfaction less late diabetic complications such as problems with eyes, kidneys or feet and myocardial infarction, stroke or death.

Insulin degludec (Tresiba) for diabetes in teenagers and children: Overview

In 2015 insulin degludec (trade name: Tresiba) was approved in Germany for the treatment of type 1 and type 2 diabetes in teenagers and children over the age of one. This drug is a long-acting insulin analogue. It is used to regulate blood sugar levels for up to 24 hours.

See all (6)

PubMed Health Blog...

read all...